Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors.

Hájková, R

Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors. [electronic resource] - Folia biologica 1999 - 227-31 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

0015-5500


Animals
CD4-Positive T-Lymphocytes--immunology
Cancer Vaccines--therapeutic use
Carcinoma--immunology
Combined Modality Therapy
Cross Reactions
Cytotoxicity Tests, Immunologic
DNA, Complementary--genetics
Disease Progression
Genetic Therapy
Immunotherapy, Active
Interleukin-2--genetics
Killer Cells, Natural--immunology
Mice
Mice, Inbred C57BL
Neoplasm Recurrence, Local--prevention & control
Neoplasm Transplantation
Neoplasm, Residual
Recombinant Fusion Proteins--physiology
Sarcoma, Experimental--metabolism
Spleen--immunology
T-Lymphocytes, Cytotoxic--immunology
Transfection
Tumor Cells, Cultured--immunology
Vaccination